CLINICAL_TRIALS
trial_result
· 2026-02-20
Clinical Trial Update: Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC [Phase 2]
Summary
Phase 2 trial of poziotinib for EGFR exon 20-mutant or ERBB2-mutant advanced non-small cell lung cancer was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: EGFR Exon 20 Mutation, ERBB2 Gene Mutation | Phase 2 | Status: TERMINATED